JAK1 and acute myeloid leukemia: Phase 1 of the phase 1/2 study was conducted to assess INCB052793, a potent JAK1 inhibitor, alone and in combination with standard therapies for patients with MM, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) [62].